Great news for the Colorado bio-scape…
Replidyne Inc., a Louisville, Colorado based drug company focused on anti-infectives, has filed a registration statement with the SEC for a proposed initial public offering of its common stock. It plans to trade on the Nasdaq under ticker symbol RDYN, with Merrill Lynch and Morgan Stanley serving as lead underwriters. Replidyne has raised around $123 million in total VC funding since its 2000 inception, from firms like Morgenthaler, HealthCare Ventures, Perseus-Soros, Sequel Venture Partners, TPG Ventures and Duquesne Capital Management
Thursday, April 06, 2006
The Best News I’ve Heard Today!
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment